Antibody-Drug Conjugates for Cancer Treatment

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies enable targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic index.
• Antibody-drug conjugates (ADCs) comprise an antibody, cytotoxic payload, and linker, crucial for anticancer efficacy.
• The success of approved ADCs has spurred extensive research, with over 65 agents in clinical evaluation.

Purpose of the Study:

• To review antibody-drug conjugates (ADCs) in clinical development for cancer treatment.
• To highlight ADCs approved for marketing, in pivotal trials, or in Phase II development.
• To discuss the components and biological factors critical for effective ADC design.

Main Methods:

• Literature review of approved and investigational antibody-drug conjugates.
• Analysis of ADCs in pivotal clinical trials and Phase II development.
• Examination of components: antibody, cytotoxic payload, linker chemistry, and target antigen.

Main Results:

• Several ADCs have been approved, including brentuximab vedotin and ado-trastuzumab emtansine.
• Over 65 ADCs are currently undergoing clinical evaluation for various cancers.
• ADCs are being developed for both hematologic malignancies and solid tumors.

Conclusions:

• Antibody-drug conjugates represent a promising strategy for targeted cancer therapy.
• The design of ADCs requires careful consideration of antibody, payload, linker, and antigen properties.
• Ongoing research and clinical evaluation continue to expand the therapeutic potential of ADCs.